Pfizer, Genmab cervical cancer therapy wins full FDA approval [Seeking Alpha]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Seeking Alpha
FDA accepted a supplemental Biologics License Application granting full approval for their cervical cancer therapy, Tivdak (tisotumab vedotin-tftv). Tivdak becomes the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer. The drug previously received FDA's accelerated approval in September 2021 for adults with cervical cancer who have previously undergone chemotherapy. The full approval is based on positive results from a global Phase 3 study, demonstrating overall survival benefit of Tivdak compared to chemotherapy in adult patients with previously treated recurrent or metastatic cervical cancer. The innovaTV 301 study showed a 30% reduction in the risk of death compared to chemotherapy, with median overall survival for Tivdak-treated patients being 11.5 months. The study was conducted by Seagen, which was acquired by Pfizer ( PFE ) in December 2023, in collaboration with Genmab
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress [Yahoo! Finance]Yahoo! Finance
- Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressBusiness Wire
- Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Financial Results for the First Quarter of 2024 [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Financial Results for the First Quarter of 2024GlobeNewswire